The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. - Wikidata - wikimedia - TriplyDB

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

http://www.wikidata.org/entity/Q42511189

about

Understanding and treating triple-negative breast cancer Risk factors for triple-negative breast cancer in women under the age of 45 years The role of preoperative systemic treatment in patients with breast cancer The fate of chemoresistance in triple negative breast cancer (TNBC)The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer Current approaches in treatment of triple-negative breast cancer Genomic profiling in triple-negative breast cancer Cancer-associated fibroblasts in digestive tumors Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.Systemic treatment strategies for triple-negative breast cancer.Neoadjuvant therapy in the treatment of breast cancer Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms A perspective on anti-EGFR therapies targeting triple-negative breast cancer Triple-negative breast cancer: is there a treatment on the horizon?Role of positron emission tomography for the monitoring of response to therapy in breast cancer Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin A phenotypic mouse model of basaloid breast tumors Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer FPA-FTIR Microspectroscopy for Monitoring Chemotherapy Efficacy in Triple-Negative Breast Cancer.A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.Point success rate for patient therapeutic response prediction by continuous biomarker scores.Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers.Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy Breast Cancer Prognostics Using Multi-Omics Data.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

P2860

Q24620957-61F3D233-ABAC-489A-8288-6466030FED6E Q24644075-4342E846-706E-454E-8A07-BDF3A2A8400C Q26746034-34057F2D-A7EB-4547-B4F5-21FC1A111191 Q26775232-68A72387-B6B7-43DF-9FEA-4BEF7D102FDD Q26785448-5BDF43CF-EDFD-43C6-9BCE-BBF917DC0ACB Q26798419-AB04E1F4-9EF6-49F4-A952-A1AE2AFC866A Q26801549-65B521B1-19D9-49DE-9762-77BEBA62842C Q27015775-E391A327-1B99-48CB-A81A-BCCAF6AC0882 Q27022816-C8A0FBB9-756A-4D66-B73E-071BC6EC090F Q27022834-3FEBBEBA-E2CF-41BC-AC01-EE0E04649BAA Q27300459-59C64429-D5AE-4465-869D-476ECB68D352 Q27691414-DA78C9B4-CCF0-451F-95F8-CA081D1D6AC0 Q27694514-D38AC2FC-9912-421E-A16B-16C2F91D9D8E Q28066481-00A2022A-4ED8-4C02-8F6C-593E7C6FEDC1 Q28066752-0D13D859-CA22-4A49-B765-EA54A02477A8 Q28069867-71BA0AF5-AF94-4FD8-BD83-45E14086DCA0 Q28077243-116BD297-F768-4BB0-A6EB-F007185541AA Q28080621-C71CBC5C-61B1-4FB1-AFBD-81DFCE25C6E4 Q28372484-A65A0B3B-12E0-4BC9-A8FB-3056C5863B0A Q28387216-83A5C8BA-7103-4FAC-A3B9-3356F987E746 Q28394618-4D0A677E-C8C0-40A9-A23D-2DE0264E1DA9 Q28468665-33C57062-8A7D-4362-BA86-D0238F31792F Q28480588-956A9CA5-C820-4432-AB49-3CE14C89579D Q28484040-AC9A3493-16B9-43C2-86E0-B60356FD0208 Q28535227-2AA42DEF-DECC-48F2-9CD9-6C561357BD86 Q28821187-1C173024-E08B-4946-A78B-216A70EEBB65 Q28828213-5B4D5E4F-01BF-41E8-9BF9-662019CD39A5 Q29616360-46CCCFC9-717F-4F28-A1BF-E0F1C6867A25 Q29617680-0FDE635D-A796-4DCC-B440-389C1B9A19C4 Q29619481-39AC9F78-17CD-4EEF-A635-C07FEC7B177F Q30369230-98C6389C-5775-4B20-A57A-6895292522C9 Q30423830-0F2815D1-D1E3-46F8-8ABC-73BB24108EAC Q30456795-0427FABB-2595-4A67-90AE-55CDE5520B55 Q30474511-3CF89910-C603-414C-830A-8708D640641D Q30477571-CB5DE6E7-6C6C-4DF3-887D-C4241EB983BF Q30541773-51CD920E-37B6-4A76-A956-1F57765DCBA8 Q30665329-9D90C908-5B42-4A1C-BB02-DB1E7BCEA909 Q30682911-89F2F0D0-2223-4CB5-8522-11456ECF9E91 Q31124796-D019F70F-1030-4FC7-A021-2E208FD4F62F Q33291587-070E9D06-F51A-4805-B5A0-1876999F5623

P2860

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

http://www.wikidata.org/entity/Q42511189

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

@en

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

@nl

type

label

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

@en

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

@nl

prefLabel

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

@en

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

@nl

P1433

Q42511189-177F66E9-1DEC-4F8D-AA9E-3D3497F4373C

P1476

Q42511189-1933EC42-3420-473B-9C9B-EEB5E6FA0907

P2093

Q42511189-03F48724-5183-48D8-A9C7-50BCA030FC42

Q42511189-1723C414-CF62-4E54-8D0F-F1026C0B3585

Q42511189-366B33B1-94CF-4FA0-A1B8-01819B898DBA

Q42511189-602AFA29-8AE5-4B23-955A-738FF5B1D3AE

Q42511189-972CB2B3-6E83-4669-848E-75D382A04995

Q42511189-9A6ADFDF-F93B-40A6-A73E-594D2C2DA33E

Q42511189-B1AB1300-AEA2-4FB9-8326-7A4B0DB916BD

Q42511189-CBF3D0AC-5FB2-4395-A1BD-5E0BE468096A

Q42511189-EB27B363-9B1D-42AE-B70A-202F6FEC3FA9

P304

Q42511189-8DFEC3C4-E229-4269-BD67-1A68476C9EE6

P31

Q42511189-D4005DDF-1A9C-4985-ADCD-8DE964DEDA59

P356

Q42511189-64ADB729-A0D0-44B6-B5C9-34AF77816416

P407

Q42511189-C5025E6A-2462-47B7-9EC3-3927F30B2BEF

P433

Q42511189-8E674C7E-0BE5-4FA4-8A7E-74CBF7EBEC05

P478

Q42511189-4E54E97B-EA43-41AD-9D67-CA03C470C08B

P50

Q42511189-7C1857A8-BD17-4753-996D-8C65CF4B6D82

P577

Q42511189-E700F600-328B-4720-9E9F-3570579DB852

P698

Q42511189-3B993691-65C3-4E08-8965-DD989A35F1E9

P356

1078-0432.CCR-06-1109

P1433

Clinical Cancer Research

P1476

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

@en

P2093

Carolyn I Sartor

http://www.w3.org/2001/XMLSchema#string

David W Ollila

http://www.w3.org/2001/XMLSchema#string

Dominic T Moore

http://www.w3.org/2001/XMLSchema#string

E Claire Dees

http://www.w3.org/2001/XMLSchema#string

Frances Collichio

http://www.w3.org/2001/XMLSchema#string

Lisa A Carey

http://www.w3.org/2001/XMLSchema#string

Lisa Gatti

http://www.w3.org/2001/XMLSchema#string

Lynda Sawyer

http://www.w3.org/2001/XMLSchema#string

Mark L Graham

http://www.w3.org/2001/XMLSchema#string

P304

2329-2334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-1109

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Charles M. Perou

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17438091

http://www.w3.org/2001/XMLSchema#string